A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial

Chronic Fatigue Syndrome Clinical Trial

— REVIVE  

Official title:

An Adaptive, Randomized, doublE-blind, Placebo-controlled, Prospective, Pharmacological interVention Study In Participants With Long COVID-19 Syndrome: REVIVE-TOGETHER Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06128967
• Other study ID #: TOGETHER_REVIVE
• Status: Recruiting
• Phase: Phase 3
• Start date: October 18, 2023
• Est. completion date: May 18, 2025

Study information

• Verified date: November 2023
• Source: Cardresearch
• Contact: Gilmar Reis, MD, PhD
• Phone: +553132416574
• Email: greis[@]cardresearch.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Date of notification letter to the IRB informing start of recruitment activities: October 21, 2023. Long COVID is a multi-systemic condition comprising often severe and persistent symptoms (longer than 12 weeks) that follow a known episode of COVID-19 and cannot be explained by another medical condition. This condition is observed in up to 15% of all individuals after an acute episode of COVID-19, even in those who had a mild and oligosymptomatic SARS-CoV-2 infection. Around 40% of these patients present symptoms that significantly compromise their daily activities. There is increasing evidence that LONG COVID is accompanied by dysregulated, persistent and uncontrolled inflammation, often accompanied by the development of an autoreactive immune response, including autoantibodies. Symptoms can last months or years, particularly in cases of chronic fatigue syndrome, with significant proportions of individuals having significant chronic impairment, preventing the performance of work and social activities.

Description:

There is currently no approved therapies for Long COVID. Several clinical trials have been developed to address this clinical condition, however the results were based on small-scale pilot studies. We developed this adaptive, large-scale, prospective, double-blind clinical trial to evaluate the effect of chronic immune-inflammatory modulation on persistent Long-COVID symptoms.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1500
• Est. completion date: May 18, 2025
• Est. primary completion date: October 18, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age 18 years or older at the time of screening.

2. Willing and able to provide written informed consent, or with a legal representative who can provide informed consent (where approved locally and nationally).

3. Previous confirmed case of SARS-CoV-2 infection (e.g., reports having a positive nucleic acid amplification test or a professional-use SARS-CoV-2 rapid antigen diagnostic test or positive self-test).

4. Participants with a clinical picture compatible with LONG COVID according to international definitions: (www.nice.org.uk/guidance/ng188, https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID -19_condition-Clinical_case_definition-2021.1), and fatigue symptoms with an average score of at least 03 on the Fatigue Analog Scale (FSS)

5. Not currently hospitalized or requiring hospitalization, or having been hospitalized in an intensive care center at the time of the COVID-19 episode.

6. Participants with the following vital data:

1. Heart Rate between 55 and 100 bpm;

2. Temperature below 38o C;

3. Oxygen saturation = 95%.

7. Patients of childbearing potential or with partners of childbearing potential must agree to use adequate contraception during the study and up to 90 days of follow-up.

8. The symptoms of fatigue cannot be attributed to any other cause (in the researcher's opinion).

9. Willingness to follow all study procedures.

Exclusion Criteria:

1. Known acute SARS-CoV-2 infection;

2. Inability to understand the content of the Informed Consent Form or to follow the study procedures;

3. Known previous diagnosis of malignant encephalomyelitis/chronic fatigue syndrome, unrelated to SARS-CoV-2 infection;

4. Known pre-existing dysautonomia, unrelated to SARS-CoV-2 infection;

5. Diabetes mellitus (exclusion criteria for the Metformin and Metformin Placebo arm);

6. Known stroke within 3 months prior to screening;

7. Known severe anemia, defined as < 8 g/dl;

8. Body Mass Index (BMI) > 35.

9. Known diagnosis of Lyme disease;

10. Any use of illicit drugs not related to marijuana within 30 days prior to informed consent;

11. Pregnant women or women of childbearing age who do not agree to practice an effective method of contraception within 90 days from the date of signing this consent form;

12. Breastfeeding women;

13. Participants using serotonin reuptake inhibitors (donepezil, fluoxetine, escitalopran, parorexitin);

14. Participants chronically using any of the medications under evaluation (metformin and fluvoxamine);

15. Severe current comorbid psychiatric disorder (e.g., clinical depression, anxiety, sleep disorder, eating disorder, substance abuse), uncontrolled and associated with significant symptoms or requiring the use of a medication contraindicated in this research ;

16. Clinical history of moderate to severe hepatic impairment or liver cirrhosis with Child-Pugh classification C or greater;

17. Clinical history of severe lung disease with significant limitation of activities;

18. Inability of the participant to give consent or adhere to the procedures proposed in the study;

19. Taking medications which are known to cause a known side effect of chronic fatigue;

20. Known hypersensitivity and/or intolerance to Fluvoxamine or Metformin;

21. Any clinical condition which, in the investigator's opinion, may prevent participation in this research.

Related Conditions & MeSH terms

• Chronic Fatigue Syndrome
• COVID-19
• Fatigue Syndrome, Chronic
• Syndrome

Intervention

Drug:
• Fluvoxamine Maleate 100 MG
Fluvoxamine Maleate 100 mg each pills
• Placebo
Placebo talc pills of same shape, color, weight if compared with active comparator
• Metformin Extended Release Oral Tablet
Metformin Extended release oral tablets of 750 mg each pill

Locations

Country	Name	City	State
Brazil	CARDRESEARCH - Cardiologia Assistencial e de Pesquisa	Belo Horizonte	Minas Gerais
Brazil	City of Brumadinho	Brumadinho	Minas Gerais
Brazil	Governador Valadares City Public Health Authority	Governador Valadares	Minas Gerais
Brazil	City of Ibirité Public Health Authority	Ibirité	Minas Gerais
Brazil	Sociedade Padrao de Educacao Superior	Montes Claros	Minas Gerais
Brazil	Universidade Federal de Ouro Preto	Ouro Preto	Minas Gerais

Sponsors (1)

Lead Sponsor	Collaborator
Cardresearch

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Improvement on Fatigue Severity Score Scale (FSS)	Improvement on Fatigue Severity Score Scale (FSS)	Day 60 after randomization
Secondary	Improvement on Fatigue Severity Score Scale (FSS)	Improvement on Fatigue Severity Score Scale (FSS)	Day 30 after randomization
Secondary	Improvement on Fatigue Severity Score Scale (FSS)	Improvement on Fatigue Severity Score Scale (FSS)	Day 30 post Study Drug Termination (Day 90 after randomization)
Secondary	Reduction on any cause hospitalization	Reduction on any cause hospitalization	Day 60 after randomization
Secondary	Safety of metformin	Safety of metformin (intention to treat analysis)	Since randomization up to Day 60 (last IMP dose)
Secondary	Safety of Fluvoxamine	Safety of Fluvoxamine (intention to treat analysis)	Since randomization up to Day 60 (last IMP dose)
Secondary	Death of any cause	Occurrence of Death of any cause	Since randomization up to Day 60 (last IMP dose)